Kornimate/medical-research-clean huggingface dataset:
the holistic health care of post-cardiac arrest survivors: from patient's health to family resilience

Conditions: Post-Cardiac Arrest Syndrome

Summary: post-cardiac arrest mortality remains high and proper care after cardiopulmonary resuscitation is an important clinical challenge. this prospective observational cohort aims to (1) identify the factors that affect short-term and long-term survival in post-cardiac arrest survivors and (2) investigate the patients and their families' health-related quality of life and psychological well-being.

for this cohort study, adult survivors (≧20 years) of sudden cardiac arrest for more than 5 minutes after cardiopulmonary resuscitation will be enrolled. basic demographic information, clinical events throughout hospitalization, and laboratory examination results will be recorded. patients will be assessed for their neurological outcome using glasgow coma score (gcs) and cerebral performance categories (cpc) upon hospital discharge, 1, 3, 6, and 12 months after discharge. post-cardiac arrest care is clinically challenging and this study aims to evaluate not just the physical well-being but also the psychological well-being of these patients on the short-term and long-term survival. patients and their families will be assessed on their health-related quality of life and psychological well-being upon hospital discharge using the following scales: mayo-portland adaptability inventory (mpai-4), world health organization quality of life scale (whoqol-bref), impact of event scale - revised (ies-r), and family resilience framework. they will also be followed for one year after discharge at 1, 3, 6, and 12 months. data will be analyzed using the spss and sas package. odds ratios and hazards ratios will be determined for the factors that affect survival after cardiac arrest. the findings will help clinicians provide timely support to the patients and their families to promote physical and psychological well-being, and integrate them back to society as soon as possible.

Eligibility criteria:
inclusion criteria: 1. patients with non-traumatic cardiac arrest, who have successfully sustained return of spontaneous circulation for more than five minutes after resuscitation efforts. exclusion criteria: 1. under 20 years of age 2. pregnant 3. terminally ill cancer patients or cancer patients who are unwilling to receive treatment 4. when the icu is over capacity and unable to provide intensive care. 5. the patient or family members refused to participate in this study.

Keywords: post-cardiac arrest holistic care family resilience
bladder distension for pain relief in nullliparous patients undergoing diagnostic office hysteroscopy

Conditions: Hysteroscopy

Summary: this study is conducted to assess whether the passive uterine straightening of the uterus by means of bladder filling is associated with less pain experienced by nulliparous women during office hysteroscopy.

a randomized controlled study revealed that bladder filling before office hysteroscopy was associated with less pain experienced by parous women . on the other hand, a randomized study revealed that misoprostol was more effective than bladder filling in minimizing the pain experienced by postmenopausal women during office hysteroscopy. till now , no studies were conducted to detect the effect of bladder filling on the pain experienced by nulliparous women during office hysteroscopy.

Eligibility criteria:
inclusion criteria: * nulliparity exclusion criteria: * parous patients * cervical pathology * previous cervical surgery * severe vaginal bleeding.

Keywords: hysteroscopy full bladder pain
estimation of non-reimbursable costs for patients with duchenne muscular dystrophy in france

Conditions: Duchenne Muscular Dystrophy

Summary: duchenne muscular dystrophy (dmd) is a chronic neuromuscular disorder affecting approximately 150 to 200 newborns annually, predominantly males, and is characterized by progressive muscle atrophy and weakness due to a complete absence of dystrophin. dmd presents a severe phenotype, with life expectancy typically extending into the third decade. data on healthcare utilization and associated costs for dmd patients, particularly within the french healthcare context, remain limited. the epardys study aims to examine the care pathways of these patients using data from the banque nationale des données maladies rares (bndmr) and the système national des données de santé (snds), enabling a detailed characterization of patient demographics, healthcare utilization patterns, and associated costs. however, only direct costs eligible for reimbursement under the affection longue durée (ald 100%) scheme can be evaluated. additional resources are consumed by dmd patients, particularly for medical care that falls outside the scope of reimbursement. furthermore, the high level of dependency in these patients may lead to the need for home adaptations or other expenditures outside the healthcare domain but linked to the disease. informal caregiving also plays a significant role. these additional family-incurred costs must be considered. the coudumyo study will aim to estimate all relevant cost components from a societal perspective, considering both minors and adults, whether they attend school or work. the medico-social aspect of care, along with the collection of data on aids and benefits received, will offer insights into the nature of the support available to families in france. the knowledge gained regarding non-reimbursable, disease-related costs according to patient characteristics will provide a comprehensive view of the financial burden borne by patients and their caregivers. this assessment is particularly relevant in the context of emerging therapies, which may reduce these associated costs. the main objective will be to describe the resource utilization associated with dmd care that is not eligible for reimbursement, including direct medical costs not covered, medico-social expenses, direct non-medical costs, and indirect costs.


Eligibility criteria:
the patients identified are those present in the bndmr and with an up-to-date address for their follow-up centre. inclusion criteria * patients of any age with dmd diagnosed more than 6 months ago; * patient included in the bndmr, not objecting to the collection of his or her data (see bndmr 'agreement to be contacted for a protocol') and alive at the time of his or her request to participate in the study. exclusion criteria: * patient taking part in an interventional clinical study with changes to usual management (see bndmr 'patient taking part in a protocol'); * patient and/or main carer objecting to the use of their data; * patient and/or main carer whose understanding of the french language does not allow them to complete the questionnaire.
one-hour diagnostic algorithm for nstemi

Conditions: Non ST Segment Elevation Myocardial Infarction

Summary: predictable values of the 1-hour algorithm for estimating the concentration of troponin using highly sensitive reagents are 98-100% for excluding myocardial infarction (mi) and 75-80% for identifying this pathology. such algorithms are developed for the rapid confirmation or exclusion of myocardial infarction without st-segment elevation and, when combined with clinical data and electrocardiogram, are used to assess the risk of adverse course of disease and to contribute to decision making about expediency of stay in the intensive therapy unit and early discharge. in mid-1980s, a new marker of myocardial damage was proposed, namely: fatty-acid-binding protein (fabp). however, the diagnostic value of fabp cannot be interpreted unambiguously because of insufficient number of studies determining the sensitivity and specificity of the test in various manifestations of acute coronary syndrome (acs). available literature presents a wide range of reference values of fabp for mi diagnosis. reference value ranges are proposed by manufacturers of diagnostic kits based on previous studies. in addition, there is no information about the fabp changes during the first three hours of the disease, as well as there are no data on diagnostic value of changes in this indicator ("∆") in patients with acs without st-segment elevation. these considerations provide rationale and support novelty of the planned pilot study.

after enrollment in the study, patients will undergo the following procedures: 1. physical examination (at baseline) and monitoring of vital signs (blood pressure, heart rate, breathing rate) at hours 1, 2, and 3 after admission to hospital. 2. registration of 12-lead electrocardiogram (ecg) (at baseline, after 24 hours, and at the day of discharge). 3. at baseline (at the time of admission to hospital), venous blood will be obtained to perform blood tests for determination of troponin i, fabp, and cpk-mb levels. at the same time, venous blood will be sampled for routine clinical laboratory blood tests. at hours 1, 2, and 3 after admission to hospital, venous blood will be sampled for assessment of the troponin i and fabp levels. 4. echocardiography will be performed 24 hours after admission (lvedv, lvesv, and ef). at day 3, standard echocardiography will be performed.

Eligibility criteria:
inclusion criteria: * patients aged 18-80 years old * male patients * acute pain in the chest similar to myocardial infarction with/or without ecg changes * admission to the hospital within 4 hours from onset of the disease. exclusion criteria: * patients with acs in the preceding 30 days * cerebral blood circulation disorder * recent surgical intervention * extensive burns of degree 2-3 * massive wounds and injuries * percutaneous coronary intervention or cardioversion * pregnancy or lactation * malignant tumors of stage 4 * severe renal insufficiency (gfr\< 30 ml/min)

Keywords: fabp non st segment elevation myocardial infarction
efficacy and safety of plasma exchange compared to standard medical therapy in patients with severe drug induced liver injury with or without underlying chronic liver disease.

Conditions: Chronic Liver Disease

Summary: in this randomized study subject will be randomized into two groups group a will receive standard medical treatment (albumin + high caloric diet) group b will continue standard medical treatment with high volume plasma exchange. all other interventions will be at the discretion of clinicians.


Eligibility criteria:
inclusion criteria: * age-18-70 years * preferably biopsy proven or history suggestive of dili (drug induced liver injury) 1. grade iv dili with t.b \> 15 2. dili manifesting as aclf (acute on chronic liver failure) /alf (acute liver failure) with no transplant option exclusion criteria: * evidence of active infection * refusal of consent or assent * patients with clinical suspicion of irreversible brain injury * pregnancy * hcc (hepatocellular carcinoma) or any other malignancy * kidney failure * portal vein thrombosis * upper gastrointestinal bleed * transplant
fitness and exercise for people with arthritis

Conditions: Arthritis

Summary: the purpose of this study is to develop and evaluate a progressive, land-based exercise program, that includes muscular and aerobic conditioning, resistance and stabilization exercises and balance training, for persons with arthritis.

there is evidence that people with arthritis who participate in appropriate types of physical activity can improve physical function and pain management. most existing programs focus on improving flexibility and balance. less attention has been paid to conditioning and overall functional fitness. to address some of these concerns, this study will develop, evaluate, and implement a non-aquatic physical activity program to increase health-related functional fitness in community-dwelling adults with arthritis. specific goals are: 1. to develop a systematic and progressive program (fepa: functional exercise for persons with arthritis) that integrates muscular and aerobic conditioning, balance and trunk/pelvic stabilization exercises emphasizing joint-protective, multi-plane movement patterns that mimic those used in everyday activities. 2. implement the fepa program in an ethnically diverse, low ses community sample of older adults with arthritis. 3. conduct process, outcomes and impact evaluations to assess the effectiveness of the fepa program for increasing short- and immediate-term health and functional fitness outcomes. 4. evaluate the sustainability of the fepa program through a program logic model process and identify inputs, activities and outputs that contribute to successful program implementation and the building of community capacity to support long-term program maintenance.

Eligibility criteria:
inclusion criteria: * self-reported doctor-diagnosed arthritis * no physical limitations precluding exercise participation * negative screen for cvd (par-q) * age 20+ * english or spanish speaking exclusion criteria: * presence of any condition for which exercise is contraindicated * physical inability to complete exercise program

Keywords: arthritis exercise function pain
antiviral activity of oral probiotics

Conditions: Lower Respiratory Tract Infection; Upper Respiratory Tract Infection

Summary: the aim of this study is to test saliva samples obtained from healthy human participants for anti-viral activity after they have consumed s. salivarius probiotic in a powder format.

this is a randomized controlled open pilot study to evaluate saliva samples collected from participants following their consumption of powders containing the commercially marketed probiotic bacterium s. salivarius k12 or s. salivarius m18. participants will be randomly assigned to one of the 4 groups consuming probiotic powder containing streptococcus salivarius k12 or s. salivarius m18 with or without prebiotics (e.g. sugars that may promote probiotic activity). saliva samples will be collected at predetermined time points pre and post intervention. antibacterial and antiviral activity will be determined following established assays. colonisation efficacy will be determined by enumerating the probiotic in the saliva samples using standard microbiological techniques.

Eligibility criteria:
inclusion criteria: 1. in general good health 18 - 80 years of age. 2. practice good oral hygiene. exclusion criteria: 1. have a history of autoimmune disease or are immunocompromised. 2. are on concurrent antibiotic therapy or regular antibiotic use within last 1 week 3. history of allergy (e.g. dairy).

Keywords: streptococcus salivarius k12 probiotic antiviral activity antibacterial activity microbial colonization oral probiotic powder prebiotic
decision making in men with early stage prostate cancer patients and partners/close allies

Conditions: Low Risk Prostate Cancer

Summary: the purpose of this study is to collect information on how patients and their partners/close allies make treatment decisions when they have been diagnosed with early stage prostate cancer.

each patient and his partner will fill out assessments at baseline. thereafter we will obtain the patients' treatment decision (at or as) within approximately 6 months. once a patient makes a decision, he and his partner will complete another set of questionnaires. the patient and his partner will then complete the remaining questionnaires approximately 6, 12, 18, and 24 months following the treatment decision. we will examine the associations between baseline assessments , and the treatment decision as well as the changes in the assessments and the treatment decision. we will also assess associations between follow-up assessments and the decision to change a treatment decision from as to at. data from patients and partners/close allies will generally be analyzed separately, thus patients who do not have a partner (or partner declines to participate) can still be enrolled and their psychosocial outcomes assessed.

Eligibility criteria:
inclusion criteria: for patients: * men who meet the nccn guidelines for low risk prostate cancer, which include all of the following: * most recent gleason score ≤ 6, or clinical stage t1a or less; * most recent psa level below 10; * in the most recent biopsy, had fewer than 3 positive biopsy cores (with ≤ 50% cancer in each); or the patient's doctor discussed active surveillance as a treatment option (as documented in visit notes of the patient's medical record) * are able to speak, read, write and understand english well enough to provide informed consent and complete study tasks * has not made a treatment decision prior to consent, as per self report * 18 years of age or older for partners/close allies: * considered a partner/close ally to the patient in the treatment making decision, as reported by the patient * are able to speak, read, write and understand english well enough to provide informed consent and complete study tasks * 18 years old or older exclusion criteria: for patients: * history of a cancer other than prostate cancer and non-melanoma skin cancer * significant psychiatric or cognitive disturbance sufficient, in the investigator's judgment, to preclude providing informed consent or participating in the study activities (i.e., acute psychiatric symptoms which require individual treatment) for partners/close allies: * significant psychiatric or cognitive disturbance sufficient, in the investigator's judgment, to preclude providing informed consent or participating in the study activities (i.e., acute psychiatric symptoms which require individual treatment)

Keywords: assessments 13-076
the glittre activities of daily living test in chronic low back pain

Conditions: Chronic Low Back Pain

Summary: the aim of our study is to investigate the validity and reliability of the glittre activities of daily living test in individuals with chronic low back pain.


Eligibility criteria:
inclusion criteria: * diagnosed with chronic low back pain * chronic low back pain for at least the last 3 months * being aged 18-65 * voluntary participation in the study exclusion criteria: * having orthopedic or neurological impairments * history of surgery due to chronic low back pain in the last 6 months * being pregnant * participating in regular physical activity in the past 3 months
efficacy and safety of alogliptin used combination with thiazolidine in participants with type 2 diabetes in japan

Conditions: Type 2 Diabetes Mellitus

Summary: the purpose of this study was to evaluate the efficacy and safety of alogliptin, once daily (qd) combined with a thiazolidine taken qd in type 2 diabetic patients with uncontrolled blood glucose.

both insulin hyposecretion and insulin-resistance are considered to be involved in the development of type 2 diabetes mellitus. takeda is developing syr-322 (alogliptin) for the improvement of glycemic control in patients with type 2 diabetes mellitus. alogliptin is an inhibitor of the dipeptidyl peptidase iv (dpp-iv) enzyme. dpp-iv is thought to be primarily responsible for the degradation of 2 peptide hormones released in response to nutrient ingestion. it is expected that inhibition of dpp-iv will improve glycemic control in patients with type 2 diabetes. the present study was planned to evaluate the efficacy and safety of alogliptin as an add-on to pioglitazone in type 2 diabetic patients with uncontrolled blood glucose despite treatment with pioglitazone as well as diet and exercise therapies.

Eligibility criteria:
inclusion criteria: 1. had been taking pioglitazone at a stable dose (15 mg/day or 30 mg/day) for at least 16 weeks prior to the start of the treatment period (week 0). 2. had glycosylated hemoglobin (hba1c) of 6.5% or more and below 10.0% at 14 weeks after the start of the observation period (week -2). 3. had hba1c difference within 10.0%\* at 10 weeks after the start of the observation period (week -6) and 14 weeks after the start of the observation period (week -2) from 10 weeks after the start of the observation period (week -6) (\*rounded off to the first decimal place). 4. was receiving specific diet and exercise (if any) therapies during the observation period. exclusion criteria: 1. had taken a diabetic medications other than pioglitazone within 16 weeks before the start of the treatment period (week 0). 2. had a history or symptoms of cardiac failure.

Keywords: diabetes mellitus - type2 diabetes mellitus drug therapy
a study of ocrelizumab in participants with primary progressive multiple sclerosis

Conditions: Multiple Sclerosis, Primary Progressive

Summary: this randomized, parallel group, double-blind, placebo controlled study will evaluate the efficacy and safety of ocrelizumab in participants with primary progressive multiple sclerosis. eligible participants will be randomized 2 : 1 to receive either ocrelizumab or placebo.


Eligibility criteria:
inclusion criteria: * diagnosis of primary progressive multiple sclerosis (according to revised mcdonald criteria) * edss at screening from 3 to 6.5 points * disease duration from onset of ms symptoms less than (\ ) 5.0; \ /=) 5.0 * sexually active male and female participants of reproductive potential must use two methods of contraception throughout the study treatment phase and for 48 weeks after the last dose exclusion criteria: * history of relapsing remitting ms, secondary progressive, or progressive relapsing ms at screening * inability to complete an mri (contraindications for mri) * known presence of other neurologic disorders * known active infection or history of or presence of recurrent or chronic infection * history of cancer, including solid tumors and hematological malignancies (except for basal cell, in situ squamous cell carcinomas of the skin and in situ carcinoma of the cervix that have been excised and resolved) * previous treatment with b-cell targeted therapies (e.g. rituximab, ocrelizumab, atacicept, belimumab, or ofatumumab) * any previous treatment with lymphocyte trafficking blockers, with alemtuzumab, anti-cluster of differentiation 4 (cd4), cladribine, cyclophosphamide, mitoxantrone, azathioprine, mycophenolate mofetil, cyclosporine, methotrexate, total body irradiation, or bone marrow transplantation * any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study